Mitesh

As part of our Funding & Reimbursement Shorts  series, Community Pharmacy England’s in-house Drug Tariff and funding experts have created a new video on claiming payment for EPS prescriptions. EPS submission is a key part of ensuring pharmacy teams are paid accurately and on time for the medicines and services they provide. Getting the submission right helps [...]

The post Funding & Reimbursement Shorts: Claiming payment for EPS prescriptions appeared first on Community Pharmacy England.

Community Pharmacy England on behalf of pharmacy owners made further applications to the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA), resulting in a further 19 new products being added to the ‘Drugs for which Discount is Not Deducted’ (DND) list from 1 November 2025. This takes the total [...]

The post 19 products added to the Discount Not Deducted (DND) list from November 2025 appeared first on Community Pharmacy England.

MHRA Class 2 Medicines Recall: Compound Sodium Lactate Solution for Infusion BP (Hartmann’s Solution for infusion) in Viaflo 1000ml (Baxter Healthcare Limited) Drug alert number: EL(25)A/46 Date issued: 28 October 2025 Baxter Healthcare is recalling one batch of Compound Sodium Lactate (Hartmann’s Solution) 1000mL. This is due to a packaging error where some cartons labelled [...]

The post MHRA Class 2 Medicines Recall: Compound Sodium Lactate Solution for Infusion BP (Hartmann’s Solution for infusion) in Viaflo 1000ml (Baxter Healthcare Limited) appeared first on Community Pharmacy England.

NHS Business Services Authority (NHSBSA) has identified a very small number of pharmacies that are declaring consistently and significantly above their actual number of prescription items dispensed each month when submitting their FP34C declaration via the Manage Your Service (MYS) portal. Given the Government’s obligations for Managing Public Money, the Department of Health and Social [...]

The post Changes to Advance payments for pharmacies that consistently over-declare items on FP34C appeared first on Community Pharmacy England.

From 1 October 2025, generically written prescriptions for Tadalafil and Vardenafil preparations will no longer require the prescriber ‘SLS’ endorsement. However, the SLS endorsement requirements will continue to apply to the following branded versions – Cialis® and Levitra® which may only be ordered on NHS prescriptions issued for the treatment of erectile dysfunction in restricted circumstances. [...]

The post SLS endorsement requirements removed for Tadalafil and Vardenafil appeared first on Community Pharmacy England.